Q1 2024 EPS Estimates for Perspective Therapeutics, Inc. Boosted by Analyst (NYSEAMERICAN:CATX)

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Free Report) - Equities researchers at B. Riley increased their Q1 2024 EPS estimates for Perspective Therapeutics in a note issued to investors on Tuesday, April 9th. B. Riley analyst Y. Zhi now expects that the company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.03). B. Riley has a "Buy" rating and a $1.70 price objective on the stock. The consensus estimate for Perspective Therapeutics' current full-year earnings is ($0.10) per share. B. Riley also issued estimates for Perspective Therapeutics' FY2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.09) EPS.

Separately, Oppenheimer reissued an "outperform" rating and set a $1.50 target price (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st.

Perspective Therapeutics Trading Up 3.5 %

CATX stock traded up 0.05 during midday trading on Friday, reaching 1.47. 5,104,600 shares of the company's stock traded hands, compared to its average volume of 3,688,482. The stock has a market cap of $862.77 million, a price-to-earnings ratio of -14.70 and a beta of 1.56. The company has a quick ratio of 1.07, a current ratio of 1.07 and a debt-to-equity ratio of 0.02. Perspective Therapeutics has a fifty-two week low of 0.21 and a fifty-two week high of 1.60.

Institutional Investors Weigh In On Perspective Therapeutics

Institutional investors have recently bought and sold shares of the stock. Taylor & Morgan Wealth Management LLC lifted its holdings in Perspective Therapeutics by 8.7% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after acquiring an additional 50,000 shares during the last quarter. Wealth Effects LLC acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $30,000. Charles Schwab Investment Management Inc. acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $32,000. Creative Planning acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $35,000. Finally, Bank of New York Mellon Corp acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Insider Buying and Selling at Perspective Therapeutics

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Markus Puhlmann purchased 280,000 shares of the stock in a transaction dated Wednesday, January 24th. The shares were purchased at an average price of 0.50 per share, with a total value of 140,000.00. Following the transaction, the insider now directly owns 1,375,425 shares of the company's stock, valued at approximately 687,712.50. The disclosure for this purchase can be found here. Insiders acquired a total of 60,758,439 shares of company stock worth $57,576,503 over the last 90 days. Insiders own 5.72% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.